Mechanism of Action
FGFR1c/beta-Klotho Signaling
FGF-21 binds FGFR1c with low affinity alone but with high affinity when beta-klotho is present as co-receptor. The ternary complex (FGF-21/beta-klotho/FGFR1c) activates RAS/MAPK and PI3K/Akt pathways. In adipose tissue, this promotes adiponectin secretion and glucose uptake (GLUT4 translocation). In liver, FGFR2c/beta-klotho signaling reduces SREBP1c-driven lipogenesis and promotes fatty acid oxidation (PPARalpha target genes).
Multi-Tissue Metabolic Effects
Liver: FGF-21 suppresses hepatic lipogenesis, reduces liver fat (NAFLD/MASH benefit), and promotes VLDL assembly changes that lower plasma triglycerides. Adipose: promotes thermogenesis in brown adipose via UCP1 induction, drives "beige" adipocyte differentiation, and increases adiponectin (an insulin-sensitizing adipokine). CNS (hypothalamus): reduces sugar and alcohol preference, decreases appetite. Combined, these effects produce comprehensive metabolic improvement resembling a lean, fasted metabolic state.
Research Summary
MASH/NASH (Liver Fat)
Phase 3Efruxifermin (AKR-001, long-acting FGF-21 analog) HARMONY Phase 3 for MASH: 39% of patients achieved MASH resolution without fibrosis worsening vs 19% placebo at week 24. Fibrosis improvement by 1+ stage in 40% vs 25% placebo. Multiple Phase 3 trials ongoing across the MASH drug landscape, with FGF-21 analogs as leading candidates. Pegbelfermin (BMS-986036) showed 26% relative liver fat reduction in Phase 2.
Dyslipidemia
Phase 2FGF-21 analogs produce dramatic triglyceride lowering (40-60%), LDL reduction, and HDL elevation -- a lipid profile shift not achievable with statins alone. Efruxifermin Phase 2 in hypertriglyceridemia: 72% TG reduction. This positions FGF-21 analogs as potential drugs for severe hypertriglyceridemia, cardiovascular risk reduction, and metabolic syndrome.
Alcohol and Food Intake (CNS)
Active ResearchFGF-21 in the hypothalamus (VMH, anterior cingulate) reduces sweet and alcohol preference in rodent and non-human primate studies. This CNS action raises the possibility that FGF-21 analogs could reduce cravings and addictive food/alcohol intake as part of their metabolic benefit profile.
Calculate your FGF-21 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Metabolic/NASH research | 1-10 mg/kg SC daily or efruxifermin equivalent in mouse NASH models | Daily or 3x/week | Subcutaneous |
| Lipid research | FGF-21 protein 1-5 mg/kg SC in hyperlipidemic diet models | 3x/week | Subcutaneous |
Native FGF-21 has a ~1 hour half-life requiring frequent dosing; long-acting analogs (Fc-fusion, PEGylation) are standard in trials. Native FGF-21 available for acute mechanistic studies.
Interactions
Safety Profile
Native FGF-21: nail brittleness and hair thinning (likely via FGF receptor effects in skin appendages) in early trials. Injection site reactions. Bone loss concerns based on animal models (FGFR activation in osteoblasts reduces bone formation); bone density monitoring in trials. No significant hypoglycemia, hepatotoxicity, or cardiovascular events. Efruxifermin Phase 2/3: diarrhea, nausea (15-20%), injection site reactions, nail effects. No serious adverse events attributed to efruxifermin in reported cohorts. Long-term safety data accumulating in Phase 3 programs.
References
- [1]Kharitonenkov A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-1635.
- [2]Harrison SA, et al. Efruxifermin for the treatment of MASH (HARMONY). N Engl J Med. 2024;391(20):1909-1920.
- [3]Markan KR, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes. 2014;63(12):4057-4063.